pharmaphorum17h
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...
FiercePharma1d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a ...
CSR Wire2d
Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
BioWorld1d
Skin deep: Organon buys Dermavant for $1.2B
Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...
bovnews2d
Organon & Co (OGN) Stock Sees Market Value Hit $5.38 billion: What Are the Implications?
Organon & Co (OGN) stock saw a modest uptick, ending the day at $20.88 which represents a slight increase of $0.41 or 2.00% from the prior close of $20.47. The stock opened at $20.51 and touched a low ...